# US 2020/0138771 A1 · Anti-tumoural effects of cannabinoid combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138771 A1
- Document ID: US20200138771A1
- Status: Published application
- Kind: A1
- Application number: 16/434,616
- Filed: 2019-06-07
- Published: 2020-05-07
- Earliest claimed: 2008-06-04
- Assignees: GW Pharma Limited
- Applicants: GW Pharma Limited
- Inventors: Guillermo VELASCO DIEZ; Manuel GUZMAN PASTOR; Mar LORENTE; Sofia TORRES; Fatima RODRIGUEZ
- Web page: https://patentgrep.com/patent/US20200138771A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multifonne (GBM).

## Claims

### Claim 1

Use of a combination of cannabinoids in the manufacture of a medicament for use in the treatment of cancer.

### Claim 2 (depends on 1)

Use as claimed in claim 1, which comprises at least tetrahydrocannabinol (THC) and cannabidiol (CBD).

### Claim 3 (depends on 2)

Use as claimed in claim 2, wherein the THC and CBD are in a ratio of from between 20:1 to 1:20 (THC:CBD).

### Claim 4 (depends on 2)

Use as claimed in claim 2, wherein the THC and CBD are in a ratio of approximately 1:1.

### Claim 5 (depends on 1)

Use as claimed in claim 1, wherein the cannabinoid content is in the range of between 5 and 100 mg of the total cannabinoids present.

### Claim 6 (depends on 1)

Use as claimed in any claim 1, where each cannabinoid is used at a level which would be considered sub-optimal if being used alone.

### Claim 7 (depends on 1)

Use as claimed in claim 1, wherein the cancer to be treated is a brain tumour.

### Claim 8 (depends on 7)

Use as claimed in claim 7, wherein the brain tumour is a glioma tumour.

### Claim 9 (depends on 8)

Use as claimed in claim 8, wherein the brain tumour is a glioblastoma multiforme (GBM).

### Claim 10 (depends on 1)

Use as claimed in claim 1, wherein the one or more cannabinoids are present as plant extracts, as pure compounds, or a combination of the two.

### Claim 11 (depends on 10)

Use as claimed in claim 10, wherein the plant extract is in the form of a botanical drug substance.

### Claim 12 (depends on 1)

Use as claimed in claim 1, wherein the one or more cannabinoids are administered separately, sequentially, or simultaneously to one another.

### Claim 13

A method for preparing a botanical drug substance, wherein the botanical drug substance comprises THC and CBD, the method comprising:
extracting THC and CBD from a cannabis plant to obtain a primary extract; and
purifying the primary extract by supercritical or subcritical extraction, vaporization and chromatography to obtain the botanical drug substance.
